Cash figures as of 2025-06-30. Database snapshot: 2026-09-21.
Price history
Loading RADX daily closes…
Loading price history…
Pipeline assets
177Lu-BetaBart
Stage not disclosed · ActiveModality: radioantibody (177Lutetium-conjugated anti-B7-H3)
Target B7-H3
Partnerships AtomVie Global Radiopharma (development and manufacturing services)
Status note 177Lutetium-conjugated B7-H3 radioantibody. Phase and indication not disclosed in the filing; other licensed programs in the 20-F do not name distinct candidates with stages and indications.
Per-asset detail extracted from the 20-F filed 2025-09-18. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
No specialist-fund holders in 13F data for this company.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.